What This Document Is
This document is a research article examining the impact of delayed chemotherapy-induced nausea and vomiting (CINV) on patients, healthcare resource use, and associated costs within German cancer centers. It presents the findings of a prospective, multi-center study investigating the occurrence and economic consequences of CINV in patients undergoing emetogenic chemotherapy. The study focuses on both direct costs (medication, visits) and indirect costs (lost workdays).
Why This Document Matters
This article is valuable for healthcare professionals – particularly nurses, pharmacists, and healthcare administrators – involved in oncology care. It’s relevant for understanding the often-overlooked economic burden of CINV, beyond the clinical impact on patients. The findings can inform decisions regarding antiemetic treatment protocols and resource allocation within cancer treatment facilities. Researchers in health economics and pharmaceutical outcomes will also find this study insightful. It’s used to justify improved preventative measures and potentially more effective antiemetic strategies.
Common Limitations or Challenges
This study is specific to the German healthcare system. While the findings regarding CINV prevalence and impact are broadly applicable, the cost figures (€49 and €48 per patient) will vary significantly in other countries due to differences in healthcare pricing and reimbursement models. The study also focuses on patients receiving highly emetogenic chemotherapy (levels 4 or 5), so the results may not directly translate to patients receiving less aggressive regimens.
What This Document Provides
The full article includes: a detailed background on CINV and its impact; a comprehensive description of the study methodology, including patient enrollment criteria and data collection methods; specific data on the incidence of acute versus delayed CINV, and nausea versus vomiting; a breakdown of healthcare resources utilized by patients experiencing CINV (rescue medications, physician visits, hospitalizations); a cost analysis from the perspectives of the third-party payer, provider, and patient; and identification of patient and treatment characteristics associated with higher CINV-related costs (cisplatin regimens, emesis, delayed CINV).
This preview does *not* include the full statistical analysis, detailed cost breakdowns, or the complete methodology used in the study. It also does not provide clinical guidelines for managing CINV.